Business Context and Reporting Period
This Form 8-K Current Report was filed by WhiteHorse Finance, Inc. on September 16, 2013. The report details a specific event regarding the repayment of a loan investment by Acella Pharmaceuticals, LLC.
Key Financial Metrics
- Principal Prepayment: Approximately $59.7 million received from Acella Pharmaceuticals, LLC.
- Pre-payment Fee: 3% of the principal amount.
- Loan Details: First lien secured term loan originally due December 30, 2015.
- Other Metrics: The filing does not provide data on total revenue, net profit, operating cash flow, margins, total debt, or liquidity ratios for the period.
Material Changes
The material change reported is the full repayment of the Acella Pharmaceuticals, LLC term loan ahead of its scheduled maturity date. This event resulted in a significant inflow of principal and a fee, altering the Company's loan portfolio composition and cash position relative to the prior period.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or discussion of new risks and contingencies. The report is limited to the disclosure of the loan repayment event under Item 8.01 (Other Events).
Investor Verification Checklist
- Verify the exact total cash received, including the calculated 3% pre-payment fee on the $59.7 million principal.
- Confirm the impact of this prepayment on the Company's current loan portfolio yield and asset quality.
- Review subsequent filings to determine how the Company deployed the returned capital.